[An immunohistochemical study of RB tumor suppressor gene protein and bcl-2 gene protein in carcinomas of the thyroid gland].
The expression of RB and bcl-2 proteins was investigated in 135 thyroid carcinomas (130 papillary carcinomas and five follicular carcinomas) by the immunohistochemical technique with RB and bcl-2 monoclonal antibodies. The results were as follows: 1) RB protein nuclear staining was shown in 117 of the 135 thyroid carcinomas (87%). Bcl-2 protein staining was shown in 82 of the carcinomas (61%). 2) There was a higher incidence of recurrence in RB-negative cases than in RB-positive cases (chi 2 test p = 0.001). But there is no significant relationship between the incidence of recurrence and the results of bcl-2 staining (chi 2 test p = 0.287). 3) The expression of RB protein was related to age and clinical N and M categories. Bcl-2 protein expression was related to clinical T categories. 4) The 10-year overall survival rate for RB-positive patients was higher than that for negative patients (long-rank test p < 0.0001). But the survival rate was not associated with bcl-2 expression (log-rank test p = 0.3). Our results suggest that assessment of RB protein expression by the immunohistochemical technique may be useful to determine the possibility of recurrence and to predict the outcome of thyroid carcinomas. We think that assessment of RB protein expression by the immunohistochemical technique can be applied as a more sensitive prognostic factor.
Ogawa
T
T
Department of Head and Neck Surgery, Aichi Cancer Center Hospital.
Hasegawa
Y
Y
Nakayama
B
B
Fujimoto
Y
Y
Kohmura
T
T
Matsuura
H
H
Koshikawa
T
T
Miyata
H
H
D018263:Adenocarcinoma, Follicular / Q000175:diagnosis*; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D002291:Carcinoma, Papillary / Q000175:diagnosis* / Q000401:mortality; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis*; D016160:Retinoblastoma Protein / Q000032:analysis*; D012680:Sensitivity and Specificity; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000401:mortality
D014408:Biomarkers, Tumor; D019253:Proto-Oncogene Proteins c-bcl-2; D016160:Retinoblastoma Protein